37 episodes

Interviews, discussion and press conferences from the EHA 2016 (European Haematology Association) Annual Meeting in Copenhagen from 9th - 12th Jun 2016.

EHA 2016 ecancer

    • Medicine

Interviews, discussion and press conferences from the EHA 2016 (European Haematology Association) Annual Meeting in Copenhagen from 9th - 12th Jun 2016.

    • video
    Older patients with AML benefit greatly from SGN-CD33 and HMA therapy combo - Dr Amir Fathi

    Older patients with AML benefit greatly from SGN-CD33 and HMA therapy combo - Dr Amir Fathi

    Dr Fathi talks to ecancertv at EHA 2016 about an ongoing phase I trial that looks at the use of vadastuximab talirine (SGN-CD33A; 33A) in combination with standard therapies (azacitidine, decitabine) in older AML patients who have declined intensive frontline therapy.

    • 6 min
    • video
    RNA regulation of JAK-STAT pathways in CML - Dr Danilo Perroti

    RNA regulation of JAK-STAT pathways in CML - Dr Danilo Perroti

    Dr Perrotti talks to ecancertv at EHA 2016 about micro RNAs (miR) which influence cell cycle progression of haematopoietic stem cells, and their role in modulating chronic myeloid leukaemia (CML).

    The JAK-STAT pathway is one of the most well known in regulating the cell cycle and growth, and Dr Perrotti discusses how miR-300 induction of activity can promote or silence leukaemia development.

    • 3 min
    • video
    Activated JAK-STAT signaling co-operates with HOXA9 to drive leukaemia - Dr Charles de Bock

    Activated JAK-STAT signaling co-operates with HOXA9 to drive leukaemia - Dr Charles de Bock

    Dr de Bock talks to ecancertv at EHA 2016 about the role of a conserved gene cluster called HOXA, and it's co-operative role in driving T-cell acute lymphoblastic leukaemia.

    He describes how HOXA mutations, especially HOXA9, are often concurrent with mutations in the cell cycle regulatory JAK pathway, and that the two of them together are strong drivers of oncogenesis.

    Dr de Bock also discusses how these pathways might be identified and regulated, giving example of the resequencing in patients that determined this genotype.

    • 4 min
    • video
    Better screening programmes needed for haematological malignancies such as leukaemia - Dr Brigitte schlegerberger

    Better screening programmes needed for haematological malignancies such as leukaemia - Dr Brigitte schlegerberger

    Dr Schlegerberger talks to ecancertv at EHA 2016 about inherited risks for haematological malignancies such as leukaemia and the screening practices surrounding them.

    She describes the current landscape of genetic screening and counselling available to patients in Europe with particular attention to known causative mutations and how these can influence patient involvement and therapy over the course of their treatment.

    She advocates for widespread testing and patient engagement, urging more awareness raising among clinicians and patients.

    • 5 min
    • video
    Results from SCHOLAR-1 trial for DLBCL patients - Prof Christian Gisselbrecht

    Results from SCHOLAR-1 trial for DLBCL patients - Prof Christian Gisselbrecht

    Prof Gisselbrecht talks to ecancertv at EHA 2016 about the SCHOLAR-1 trial, identifying patient cohorts most likely to respond to aggressive diffuse large B-cell lymphoma (DLBCL).

    He describes patient selection from an initial pool of over 800 eligible responders, and the results from the trial including the surprising short term response followed by relapse among certain subgroups.

    Prof Gisselbrecht emphasises that these are initial results, with further analysis forthcoming.

    • 5 min
    • video
    Decoding the risk of thromboembolic events in lymphoma patients - Prof Darko Antic

    Decoding the risk of thromboembolic events in lymphoma patients - Prof Darko Antic

    Prof Antic talks to ecancertv at EHA 2016 about thromboembolic events, a common risk facing lymphoma patients.Prof Antic talks to ecancertv at EHA 2016 about thromboembolic events, a common risk facing lymphoma patients.

    He describes how chemotherapy and disease increase the chances of such an event developing in patients, and the development of a prognostic score, ThroLy, to establish risk stratification for patients with up to 90.2% specificity.

    Given their frequency of these complications, Prof Antic advocates ongoing haematological analysis throughout patient admission, and anticipates further testing of ThroLy in wider applications.

    He describes how chemotherapy and disease increase the chances of such an event developing in patients, and the development of a prognostic score, ThroLy, to establish risk stratification for patients with up to 90.2% specificity.

    Given their frequency of these complications, Prof Antic advocates ongoing haematological analysis throughout patient admission, and anticipates further testing of ThroLy in wider applications.

    • 8 min

Top Podcasts In Medicine

More by ecancer